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OBJECTIVES We sought to determine whether pulse pressure (PP), a measure of arterial stiffness, is an
independent predictor of the incidence of coronary heart disease (CHD), congestive heart
failure (CHF) and overall mortality among community-dwelling elderly.
BACKGROUND Current hypertension guidelines classify cardiovascular risk on the basis of elevated systolic
blood pressure (SBP) or diastolic blood pressure (DBP) without considering their combined
effects. Recent studies suggest that PP is a strong predictor of cardiovascular end points, but
few data are available among community elderly.
METHODS The study sample included 2,152 individuals age $65 years, who were participants in the
Established Populations for Epidemiologic Study of the Elderly program, free of CHD and
CHF at baseline and still alive at one year after enrollment. Blood pressure was measured at
baseline. Incidence of CHD, incidence of CHF and total mortality were monitored in the
following 10 years.
RESULTS There were 328 incident CHD events, 224 incident CHF events and 1,046 persons who died
of any cause. Pulse pressure showed a strong and linear relationship with each end point.
After adjusting for demographics, comorbidity and CHD risk factors, a 10-mm Hg
increment in PP was associated with a 12% increase in CHD risk (95% confidence interval
[CI], 2% to 22%), a 14% increase in CHF risk (95% CI, 5% to 24%), and a 6% increase in
overall mortality (95% CI, 0% to 12%). While SBP and mean arterial pressure (MAP) also
showed positive associations with the end points, PP yielded the highest likelihood ratio
chi-square. When PP was entered in the model in conjunction with other blood pressure
parameters (SBP, DBP, MAP or hypertension stage, respectively), the association remained
positive for PP but became negative for the other blood pressure variables. The effect of PP
persisted after adjusting for current medication use and was present in normotensive
individuals and individuals with isolated systolic hypertension but not in individuals with
diastolic hypertension.
CONCLUSIONS Elevated PP is a powerful independent predictor of cardiovascular end points in the elderly.
(J Am Coll Cardiol 2000;36:130–8) © 2000 by the American College of Cardiology
Current knowledge of the role of hypertension as a major
risk factor for atherosclerotic diseases is derived mostly from
studies in young and middle-aged persons. These studies
have typically focused on systolic blood pressure (SBP) and
diastolic blood pressure (DBP) levels, without considering
their combined effects (1–5). As a result, current hyperten-
sion guidelines classify cardiovascular risk based uniquely on
SBP and DBP levels (6).
Blood pressure is a periodic phenomenon consisting of
two components: steady and pulsatile. The former is a
function of the cardiac output and the vascular resistance,
while the latter represents the variations of the pressure
curve around the steady component and depends mostly on
large artery compliance and ventricular ejection (7–9). Both
can be estimated by using combined levels of SBP and DBP:
the steady component correlates with mean arterial pressure
(MAP), while the pulsatile component correlates with pulse
pressure (PP) (7–9). Recent studies suggest that PP is a
strong predictor of cardiovascular end points (9–15), in
particular, cardiac rather than cerebrovascular end points
(10,13), and is perhaps stronger than MAP, SBP and DBP
(9,11,12,14,15). However, most of these studies were car-
ried out with selected samples (12,13) or with patients with
hypertension (11,12) or coronary heart disease (CHD) (9).
There is little information on PP as a risk factor for
cardiovascular disease and mortality in the elderly, among
whom the prevalence of a large PP is highest (16). Pulse
pressure increases progressively with age due to the fact that
while SBP continues to rise with age, DBP remains con-
stant or declines (16). In older individuals, SBP is a stronger
risk factor for cardiovascular diseases than DBP (17,18) and
parallels the strong risk carried by isolated systolic hyper-
tension (2,19). A low DBP has also been associated with
increased risk, both in older adults in the community
(20,21) and in individuals taking antihypertensive medica-
tions (12,22–27). Because of these relationships and because
PP is a combination of both systolic and DBP, it is
important to take into account the role of other blood
pressure parameters when studying the effect of PP.
From the *Department of Epidemiology and Public Health, Yale University School
of Medicine, New Haven, Connecticut and †Department of Medicine (Cardiology),
Yale University School of Medicine and Center for Outcomes Research and
Evaluation, Yale New Haven Hospital, New Haven, Connecticut. This study was
supported, in part, by contract #N01-AG-02105 from the National Institute on
Aging and by the Donaghue Medical Research Foundation Grant #95-094.
Manuscript received September 14, 1999; revised manuscript received January 17,
2000, accepted March 6, 2000.
Journal of the American College of Cardiology Vol. 36, No. 1, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)00687-2
Accordingly, the purposes of this study were to examine
the association between PP and cardiovascular end points
(incidence of CHD and of congestive heart failure [CHF]),
as well as the total mortality in an elderly community
sample, and to determine whether this association is inde-
pendent of MAP, SBP, DBP, hypertension stage (including
isolated systolic hypertension) and blood pressure lowering
treatments.
METHODS
Study population. The New Haven cohort of the Estab-
lishment of Populations for the Epidemiologic Studies of
the Elderly (EPESE) is one of four sites funded by the
National Institute on Aging (28) and the only site in which
myocardial infarction (MI) and CHF events were validated
through chart review. The sampling design of this cohort
has been described in detail elsewhere (28,29). Briefly, the
cohort was assembled in 1982 by obtaining a probability
sample of the noninstitutionalized New Haven population
65 years of age and older stratified according to housing
type. The response rate was 82%, yielding a sample at
baseline of 2,812 subjects. For the current analysis, we
excluded subjects with history of MI and with possible CHF
at baseline defined as current use of furosemide and digoxin
(n 5 421), subjects for whom blood pressure measurements
at baseline were not available (n 5 116) and subjects for
whom the cause of death could not be ascertained or the MI
could not be validated (n 5 32). Subjects who died in the
first year of follow-up were also excluded (n 5 90),
consistent with the evidence for an inverse association
between blood pressure levels and short-term mortality in
elderly cohorts (18,30), which probably results from the
confounding effects of unmeasured illness and frailty
(18,30). Similar inverse relationships were noted in our
sample. This is a customary approach when comorbidity is
suspected to influence a study end point (30). These
exclusions yielded a final sample for analysis of 2,153
individuals.
Baseline data collection. Trained interviewers assessed
demographic characteristics, medical history, health habits,
use of medications and blood pressure during a face-to-face
interview in the participants’ homes in 1982. Three seating
SBP and DBP readings were obtained after the Hyperten-
sion Detection and Follow-up Protocol (31). The averages
of the second and third blood pressure reading were used.
Pulse pressure was calculated as the difference between SBP
and DBP. Mean arterial pressure was calculated using the
formula: {[SBP 1 (DBP 3 2)]/3}. Hypertension stage was
defined following current guidelines (6) as stage I (SBP of
140 to 159 mm Hg or DBP of 90 to 99 mm Hg); stage II
or greater (SBP $160 mm Hg or DBP $100 mm Hg);
isolated systolic hypertension, stage I (SBP of 140 to
159 mm Hg and DBP ,90 mm Hg) and isolated systolic
hypertension, stages II to III (SBP $160 mm Hg and
diastolic blood pressure ,90 mm Hg).
Subjects were classified as current, past or never smokers
based on self-reported smoking status. Self-reported height
and weight were used to calculate the body mass index
(kg/m2), which was classified according to tertiles (,23, 23
to 27 and .27 kg/m2). History of stroke, diabetes mellitus
and cancer were assessed by self-report. History of exer-
tional chest pain was assessed by means of a subset of the
questions from the London School of Hygiene Chest Pain
questionnaire (32,33).
Use of medications was assessed by direct inspection of all
containers for all prescription and nonprescription medica-
tions taken over the past two weeks. The following medi-
cation classes were considered: diuretics, beta-adrenergic
blocking agents, nitrates, digitalis, oral hypoglycemics, in-
sulin and aspirin. Calcium channel blockers were not
considered, because their use was infrequent in 1982.
Subjects were classified as taking antihypertensive medica-
tions if they reported that they were currently taking
medications for high blood pressure or inspection of med-
ications revealed current use of diuretics, beta-blockers,
nitrates or nifedipine.
Study end points. Study end points were assessed over a
10-year follow-up period, from the inception of the cohort
in 1982 and continuing until December 31, 1992. The main
end points were incidence of CHD, defined as occurrence of
a new MI or CHD death, and incidence of CHF, defined as
occurrence of a new hospitalization for CHF or death from
CHF. An additional end point was total mortality. Hospi-
talizations for MI or CHF were identified through a
hospitalization surveillance in the two New Haven commu-
nity hospitals, with additional information obtained from
the Medicare Part A Beneficiary Bill History data from the
Health Care Financing Administration. Matching data on
hospitalizations from these two sources indicated that our
surveillance identified 95% of all CHD-related admissions,
therefore assuring a fairly complete assessment of hospital-
izations for MI and CHF in the study population.
Validation of MI and CHF. The medical records of all the
EPESE participants who had a discharge diagnosis of acute
MI (ICD-9-CM codes 410.0–410.9) or unstable angina
(ICD-9-CM codes 411.1 and 411.8) in the two New Haven
hospitals were reviewed to verify the diagnosis of MI, as
previously described (34). When the first event did not meet
Abbreviations and Acronyms
CHD 5 coronary heart disease
CHF 5 congestive heart failure
CI 5 confidence intervals
DBP 5 diastolic blood pressure
EPESE 5 Established Populations for Epidemiologic
Study of the Elderly
ISH 5 isolated systolic hypertension
MAP 5 mean arterial pressure
MI 5 myocardial infarction
PP 5 pulse pressure
SBP 5 systolic blood pressure
131JACC Vol. 36, No. 1, 2000 Vaccarino et al.
July 2000:130–8 Pulse Pressure and Cardiovascular Risk in the Elderly
the diagnostic criteria, subsequent hospitalizations for MI
were identified and reviewed. The medical records of all the
EPESE participants who had a principal or one of the first
three secondary discharge diagnoses of CHF (ICD-9-CM
codes 48, 402.01, 402.11, 402.91, 404.01, 404.13, 404.91
and 404.93) were also reviewed to validate the diagnosis, as
previously described (35).
Deaths ascertainment. Mortality during the 10-year
follow-up was ascertained by monitoring local newspapers’
obituary notices, information from relatives at follow-up
times and by eventually obtaining death certificates of all
deceased subjects. Information on vital status was virtually
complete (.99% of all cohort members). A single nosolo-
gist coded all death certificates according to ICD-9-CM.
Coronary heart disease mortality was identified by codes
410 to 414 and deaths from CHF by codes 428, 402.01,
402.11, 402.91, 404.01, 404.13, 404.91 and 404.93, as the
underlying cause of death.
Statistical analysis. We compared mean PP according to
levels of baseline variables, using Student t tests or analysis
of variance. In these analyses other blood pressure parame-
ters (MAP, SBP and DBP) were categorized into four
groups of 10-mm Hg pressure increments. Heart rate and
body height were categorized according to tertiles. Corre-
lation analyses between all the blood pressure parameters
were also performed.
Multivariable analyses were performed using Cox propor-
tional hazards regression models. Pulse pressure, SBP, DBP
and MAP were included as continuous variables, and the
relative risk and 95% confidence interval (CI) were calcu-
lated for 10-mm Hg increments. Because the relationship of
MAP and DBP with the study end points was not linear,
the analyses were repeated by fitting MAP and DBP as
categorical variables according to 10-mm Hg increments.
To test whether the association of PP with CHD
incidence was affected by other baseline characteristics, we
performed three sequential models. The first included PP as
the sole explanatory variable. The second included PP, age
and sex. The third model included all the previous factors,
plus other demographic characteristics (education and mar-
ital status), body mass index, cigarette smoking, medical
history (diabetes, history of stroke, history of chronic
angina), heart rate and body height. Similar analyses were
performed separately for MAP, SBP, DBP and hyperten-
sion classification. This entire analysis was repeated for
CHF incidence and total mortality.
To determine whether the effect of PP on the study end
points was independent of MAP, SBP, DBP and hyperten-
sion stage, we added these parameters, separately, to models
that included PP. To address the concern that a low DBP
might be driving the PP effect, we repeated the main
analyses after excluding individuals with DBP #70 mm Hg.
Finally, to address the possibility that the effect of PP might
be the result of excessive lowering of DBP in individuals
taking antihypertensive medications, we added current
medication use to the final models for each end point. In
addition, we examined the PP effect after stratification
according to presence of hypertension and use of antihyper-
tensive medications.
All analyses were performed using SUDAAN (Survey
Data Analysis Software Research, North Carolina) and
taking into account the stratified sampling design with
oversampling of certain strata. SUDAAN applies the Taylor
linearization procedure to compute standard errors for the
estimated regression coefficients. Weighed data provide
representative estimates for the New Haven community of
noninstitutionalized elderly.
RESULTS
Baseline characteristics. Older individuals, unmarried in-
dividuals, those with diabetes and those with history of
hypertension had higher mean PP, while current smokers
had lower mean PP (Table 1). There were positive associ-
ations between PP and use of medications such as diuretics,
beta-blockers, digitalis and oral hypoglycemics. As ex-
pected, PP was also positively associated with other blood
pressure parameters, including MAP, SBP and hyperten-
sion classification. There was no significant association
between PP and DBP. The correlation coefficients of PP
with other blood pressure parameters were 0.41 with MAP,
0.83 with SBP, 20.05 with DBP, 0.69 with hypertension
classification (no hypertension, stage I, stage II to III) and
0.66 with isolated systolic hypertension (ISH) classification
(No ISH, ISH stage I and ISH stage II to III).
Effect of PP and other blood pressure parameters on the
study end points. During the 10-year follow-up, there
were 328 incident CHD events (174 validated MIs and 154
CHD deaths with no prior MI), 224 incident CHF events
(198 validated hospitalizations for CHF and 26 deaths from
CHF with no prior CHF hospitalization) and 1,046 sub-
jects died of any cause. Pulse pressure showed a strong and
graded relationship with each of these three end points (Fig.
1). In the proportional hazard regression analysis with PP
included as a continuous variable, for each 10-mm Hg
increment in PP there was a 22% increase in risk for both
CHD and CHF and a 16% increase in risk for total
mortality (Table 2).
Baseline characteristics, in particular, age and sex, ap-
peared to explain a portion of the relationship between PP
and the study end points (Table 2). After all the baseline
factors were adjusted for, a 10-mm Hg increase in PP was
still associated with a 12% increased risk for CHD incidence
(95% CI: 1.02 to 1.22), a 14% increased risk for CHF
incidence (95% CI: 1.05 to 1.24) and a 6% increase in total
mortality (95% CI: 1.00 to 1.12) (Table 2).
Systolic blood pressure was also significantly associated
with CHD, CHF and total mortality. Mean arterial pres-
sure showed positive, but somewhat weaker, associations,
while DBP was not significantly associated with the study
end points (Table 2). When considered as a categorical
variable according to 10-mm Hg increments, DBP showed
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a U-shaped relationship with CHD incidence but no
association with either CHF incidence or total mortality
(data not shown). Diastolic hypertension was mostly asso-
ciated with CHD incidence rather than with the other end
points, while isolated systolic hypertension was mostly
associated with CHF incidence.
In the fully adjusted models of CHD incidence, the
likelihood ratio chi-square was 152.1 when the model
included PP, 145.8 when the model included MAP, 150.9
when the model included SBP and 142.1 when the model
included DBP (all with 15 degrees of freedom). In the fully
Table 1. Mean Pulse Pressure According to Level of
Baseline Variables
n
Pulse Pressure
(mean, 6 SE) p Value
Age
65–74 1,253 61.4 6 0.5 , 0.0001
75–84 705 66.6 6 0.9
$85 193 74.0 6 1.9
Gender
Men 844 63.0 6 0.6 0.08
Women 1,309 64.6 6 0.5
Education
,12 yrs 1,423 64.5 6 0.5 0.15
$12 yrs 689 63.0 6 0.7
Marital status
Not married 1,344 65.4 6 0.4 , 0.0001
Married 801 62.1 6 0.6
Cigarette smoking
Never smokers 1,105 64.8 6 0.7 *
Current smokers 447 61.6 6 1.0 0.02
Past smokers 596 64.4 6 0.6 0.67
Body mass index
#23 625 63.8 6 0.8 0.87
24–27 769 63.9 6 0.6 *
$28 574 63.6 6 0.7 0.67
Missing 185 68.0 6 2.2 0.09
Height (inches)
,63 620 66.0 6 0.8 *
63–66 805 63.2 6 0.8 0.04
$67 588 62.4 6 0.9 0.009
Missing 140 67.2 6 2.2 0.58
History of angina
No 2,046 64.2 6 0.4 0.16
Yes 104 61.6 6 1.7
History of diabetes
No 1,894 63.5 6 0.4 0.0007
Yes 258 68.2 6 1.2
History of stroke
No 2,028 64.0 6 0.3 0.43
Yes 123 65.7 6 2.1
History of hypertension
No 1,171 60.8 6 0.5 , 0.0001
Yes 978 67.9 6 0.5
Current use of medications
Diuretics
No 1,472 62.8 6 0.4 0.0005
Yes 681 66.8 6 0.9
Beta-blockers
No 1,919 63.5 6 0.4 0.007
Yes 234 68.2 6 1.6
Nitrates
No 2,074 63.9 6 0.4 0.08
Yes 79 67.9 6 2.2
Digitalis
No 1,974 63.7 6 0.4 0.03
Yes 178 68.7 6 2.1
Oral hypoglicemics
No 1,990 63.7 6 0.4 0.01
Yes 162 68.3 6 1.6
Insulin
No 2,084 64.0 6 0.3 0.29
Yes 68 67.0 6 2.8
Aspirin
No 1,473 63.4 6 0.4 0.10
Yes 680 65.5 6 1.0
Table 1. Continued
n
Pulse Pressure
(mean, 6 SE) p Value
Pulse (beats/min)
,66 571 65.3 6 0.9 *
66–75 684 64.6 6 0.5 0.51
$76 847 63.1 6 0.6 0.056
Missing 51 56.9 6 3.6 0.02
Mean arterial pressure
(mm Hg)
,90 318 55.3 6 0.8 , 0.0001
90–99 696 59.9 6 0.5
100–109 619 63.4 6 0.7
$110 520 75.5 6 0.9
Systolic blood pressure
(mm Hg)
,130 451 47.5 6 0.5 , 0.0001
130–139 530 57.7 6 0.4
140–149 414 63.0 6 0.5
$150 758 79.6 6 0.6
Diastolic blood pressure
(mm Hg)
,70 375 67.3 6 1.1 0.16
70–79 727 63.5 6 0.6
80–89 669 62.1 6 0.7
$90 382 65.6 6 1.1
Hypertension classification
No Hypertension (SBP
, 140 and DBP ,
90 mm Hg)
947 53.6 6 0.4 *
Stage I (SBP 140–159
or DBP
90–99 mm Hg)
734 65.5 6 0.5 , 0.0001†
Stage II–III (SBP $
160 or DBP $
100 mm Hg)
472 84.3 6 0.9 , 0.0001†
Isolated systolic
hypertension (ISH)
or diastolic
hypertension (DH):
ISH Stage I (SBP 140–
159 and DBP ,
90 mm Hg)
563 69.8 6 0.5 , 0.0001†
ISH Stage II–III (SBP
$ 160 and DBP ,
90 mm Hg)
261 91.2 6 1.0 , 0.0001†
DH Stage I (DBP
90–99 mm Hg)
171 53.2 6 0.8 0.72
DH Stage II–III (DBP
$ 100 mm Hg)
211 76.6 6 1.4 , 0.0001†
Numbers do not always total 2,153, because of missing values.
*Reference category; †compared with no hypertension.
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adjusted models of CHF incidence, the corresponding
values of likelihood ratio chi-square were 136.3, 128.2,
132.9 and 126.0 (all with 15 degrees of freedom). In
addition to the blood pressure parameters of interest,
covariables significantly associated with CHD incidence
were history of diabetes, history of stroke and cigarette
smoking. For CHF incidence, significant covariables were
history of diabetes, history of stroke and gender (female
gender being protective).
Role of other blood pressure parameters on the PP effect.
When MAP, DBP or hypertension classification were
added to the models that included PP, the association of PP
was practically unaffected, while that of these other factors
became negative (Table 3). Similar results were obtained
when MAP and DBP were included in the models as
categorical variables according to 10-mm Hg increments.
Role of hypertension stage. To determine whether the
effect of PP is independent of hypertension stage, we
stratified the results for CHD incidence based on hyperten-
sion classification (Fig. 2). The effect of PP was present in
normotensive individuals as well as in individuals with
isolated systolic hypertension, indicating that isolated sys-
tolic hypertension is not a major mediator of the effect of
PP. The PP effect was not seen among those with diastolic
hypertension (p for interaction ,0.02). Similar results were
seen for incidence of CHF and total mortality.
Role of low DBP and hypertension treatment. To ad-
dress the potential concern that the PP effect might be
attributable mostly to low DBP, we repeated the analyses of
Table 2 after excluding individuals with DBP #70 mm Hg
(n 5 375). This exclusion did not affect the results. The
age- and sex-adjusted estimates per 10-mm Hg increase in
PP were 1.17 for incident CHD (95% CI, 1.05 to 1.30),
1.15 for incident CHD (95% CI, 1.07 to 1.24) and 1.08 for
total mortality (95% CI, 1.01 to 1.17).
To rule out the possibility that the effect of PP might be
a consequence of excessive DBP lowering from to antihy-
pertensive treatment, we further stratified the results ac-
cording to both the presence of hypertension (SBP $ 140 or
DBP $ 90 mm Hg) and the use of antihypertensive
medications (self-report use or current use of diuretics,
beta-blockers, nitrates or nifedipine by direct inspection of
medications) (Fig. 3). Most of the PP effect on CHD risk
was actually seen in the group of normotensive subjects not
taking medications for high blood pressure. Furthermore,
addition of medications to the models did not alter the
association between PP and the study end points. These
results suggest that antihypertensive medications do not
mediate the association between PP and cardiovascular end
points.
DISCUSSION
PP as a predictor of cardiovascular end points. We found
that PP, a measure of pulsatile load (7–9,16), is a powerful
and independent predictor of the incidence of CHD and
Figure 1. Relationship between pulse pressure measured at baseline and incidence of coronary heart disease (CHD), incidence of congestive heart failure
(CHF) and total mortality.
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CHF among community elderly. After adjusting for demo-
graphic, comorbidity and CHD risk factors, a 10-mm Hg
increment in PP was associated with a 12% increased risk
for new CHD events and a 14% increased risk for CHF
hospitalizations or CHF-related deaths. Pulse pressure was
also associated with a marginally significant 6% increased
risk for total mortality. The association of PP with cardio-
vascular end points was independent of MAP, SBP, DBP
and hypertension classification and was present in normo-
tensive individuals and individuals with isolated systolic
hypertension, but not in individuals with diastolic hyper-
tension.
Pulse pressure showed a graded and linear relationship
with the study outcomes, suggesting that there is no
threshold for the increased risk. Systolic blood pressure was
also linearly related to CHD and CHF incidence, but the
relationship appeared somewhat less strong than that of PP.
Mean arterial pressure and DBP showed only weak rela-
tionships with CHD and CHF incidence. These findings
support the notion that DBP and MAP are more strongly
related to cardiovascular risk in young or middle-aged
individuals rather than in older adults (8,17).
Earlier (17) and more recent studies (9–15) have indi-
cated that PP is a strong predictor of cardiovascular end
points, in particular cardiac rather than cerebrovascular end
points (10,13). However, many of these studies were carried
out in selected populations, such as clinical samples of
patients with hypertension (11) or MI (9) or other selected
groups participating in prevention programs (10,12,13). In
addition, there is paucity of information about the risk
carried by PP in the elderly, despite the high prevalence of
a wide PP in older adults. A recent study (14) found a
graded and independent association between PP and CHF
incidence, the latter based on administrative sources, in an
Table 2. Individual Effects of Pulse Pressure, Mean Arterial Pressure, Systolic Blood Pressure, Diastolic Blood Pressure and
Hypertension Classification on the Study End Points*
Unadjusted
Adjusted for Age and
Gender
Adjusted for Age,
Gender and Other
Factors*†
RR (95% CI) RR (95% CI) RR (95% CI)
CHD Incidence
PP (per 10 mm Hg) 1.22 (1.12–1.33) 1.14 (1.05–1.25) 1.12 (1.02–1.22)
MAP (per 10 mm Hg) 1.10 (0.98–1.24) 1.09 (0.96–1.25) 1.10 (0.97–1.26)
SBP (per 10 mm Hg) 1.14 (1.06–1.22) 1.10 (1.02–1.19) 1.09 (1.01–1.18)
DBP (per 10 mm Hg) 0.96 (0.83–1.12) 1.01 (0.87–1.18) 1.04 (0.89–1.22)
Hypertension classification§
No hypertension‡ — — — — — —
ISH Stage I 1.22 (0.80–1.88) 1.11 (0.74–1.69) 1.04 (0.69–1.57)
DH Stage I 1.01 (0.60–1.69) 1.08 (0.65–1.81) 1.20 (0.72–1.98)
ISH Stage II–III 1.83 (1.15–2.91) 1.38 (0.84–2.26) 1.29 (0.81–2.06)
DH Stage II–III 1.72 (1.02–2.90) 1.63 (0.98–2.72) 1.76 (1.04–2.98)
CHF Incidence
PP (per 10 mm Hg) 1.22 (1.15–1.30) 1.16 (1.09–1.25) 1.14 (1.05–1.24)
MAP (per 10 mm Hg) 1.14 (1.01–1.28) 1.13 (0.99–1.28) 1.09 (0.95–1.25)
SBP (per 10 mm Hg) 1.15 (1.09–1.22) 1.12 (1.05–1.19) 1.09 (1.02–1.18)
DBP (per 10 mm Hg) 1.00 (0.85–1.17) 1.03 (0.88–1.21) 1.00 (0.85–1.19)
Hypertension classification§
No hypertension‡ — — — — — —
ISH Stage I 1.98 (1.19–3.29) 1.83 (1.11–3.00) 1.70 (1.03–2.82)
DH Stage I 1.42 (0.87–2.29) 1.48 (0.96–2.29) 1.47 (0.94–2.29)
ISH Stage II–III 2.26 (1.42–3.61) 1.80 (1.07–3.02) 1.71 (0.97–3.03)
DH Stage II–III 1.26 (0.69–2.29) 1.20 (0.66–2.18) 1.04 (0.57–1.91)
Total Mortality
PP, per 10 mm Hg 1.16 (1.10–1.23) 1.07 (1.01–1.14) 1.06 (1.00–1.12)
MAP, per 10 mm Hg 1.07 (1.00–1.14) 1.05 (0.98–1.13) 1.04 (0.96–1.12)
SBP, per 10 mm Hg 1.10 (1.05–1.15) 1.05 (1.01–1.11) 1.04 (0.99–1.09)
DBP, per 10 mm Hg 0.97 (0.89–1.04) 1.01 (0.94–1.10) 1.01 (0.93–1.09)
Hypertension classification§
No hypertension‡ — — — — — —
ISH Stage I 1.26 (0.94–1.68) 1.13 (0.87–1.48) 1.13 (0.87–1.47)
DH Stage I 1.23 (0.92–1.64) 1.32 (1.03–1.69) 1.38 (1.06–1.79)
ISH Stage II–III 1.66 (1.27–2.16) 1.19 (0.86–1.65) 1.14 (0.86–1.51)
DH Stage II–III 1.42 (1.00–2.04) 1.34 (0.93–1.93) 1.29 (0.88–1.89)
DBP 5 diastolic blood pressure; DH 5 diastolic hypertension; ISH 5 isolated systolic hypertension; MAP 5 mean arterial pressure; PP 5 pulse pressure; SBP 5 systolic blood
pressure.
*Each of these variables was fitted in separate models; †Education (,12 yrs vs. $12 yrs), marital status (married vs. not married), history of chronic angina, history of diabetes,
history of stroke, body mass index (#23, 24–27, $28, missing), smoking status (current, past or never smoker), heart rate and body height; ‡Reference; §No hypertension: SBP ,
140 and DBP , 90 mm Hg; ISH Stage I: SBP 140–159 and DBP , 90 mm Hg; DH Stage I: DBP 90–99 mm Hg; ISH Stage II–III: SBP $ 160 and DBP , 90 mm Hg;
DH Stage II–III: DBP $ 100 mm Hg.
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older community cohort. Our study confirms this previous
investigation using a more rigorous end point ascertainment
and clarifies the independent effect of PP from isolated
systolic hypertension, which was not addressed by previous
studies.
Role of other blood pressure parameters, hypertension
stage and hypertension treatments. Our study indicates
that the effect of PP is not merely a reflection of the
individual effects of a high SBP or low DBP, which were
both associated with an increased cardiovascular risk. The
effect of PP was not substantially decreased after adjusting
for these factors and after excluding individuals with a DBP
,70. Therefore, it appears that it is the combination of a
“higher” SBP and a “lower” DBP (resulting in a wider PP)
that provides additional risk. The risk carried by a wide PP
is also not a reflection of the presence of isolated systolic
hypertension, because it was basically unchanged after
adjustment for hypertension stage and was seen among
normotensive persons as well as individuals with isolated
systolic hypertension. Finally, the effect of PP may also not
be attributed to excessive DBP lowering among individuals
taking antihypertensive medications, because addition of
Figure 2. Age- and sex-adjusted relative risks (RR) and 95% confidence intervals for the association between pulse pressure (PP) and incidence of coronary
heart disease (CHD), after stratification according to hypertension classification. DBP 5 diastolic blood pressure; DH 5 diastolic hypertension; ISH 5
isolated systolic hypertension; SBP 5 systolic blood pressure.
Table 3. Joint Effects of Pulse Pressure and Other Blood Pressure Parameters on the Study End Points
CHD Incidence CHF Incidence Total Mortality
RR (95% CI) RR (95% CI) RR (95% CI)
PP and MAP jointly:
PP, per 10 mm Hg 1.24 (1.12–1.36) 1.23 (1.12–1.34) 1.18 (1.11–1.25)
MAP, per 10 mm Hg 0.96 (0.84–1.10) 0.99 (0.86–1.15) 0.96 (0.89–1.04)
PP and SBP jointly:
PP, per 10 mm Hg 1.27 (1.08–1.49) 1.23 (1.04–1.47) 1.21 (1.11–1.32)
SBP, per 10 mm Hg 0.96 (0.84–1.10) 0.99 (0.85–1.15) 0.96 (0.89–1.04)
PP and DBP jointly:
PP, per 10 mm Hg 1.22 (1.12–1.33) 1.22 (1.15–1.30) 1.16 (1.10–1.23)
DBP, per 10 mm Hg 0.96 (0.84–1.10) 0.99 (0.85–1.15) 0.96 (0.89–1.04)
PP and hypertension
classification* jointly:
PP, per 10 mm Hg 1.27 (1.14–1.42) 1.25 (1.11–1.39) 1.21 (1.12–1.29)
No hypertension† — — — — — —
ISH Stage I 0.83 (0.53–1.30) 1.38 (0.81–2.34) 0.93 (0.68–1.27)
DH Stage I 0.99 (0.60–1.63) 1.40 (0.87–2.26) 1.21 (0.90–1.64)
ISH Stage II–III 0.74 (0.44–1.27) 1.00 (0.49–2.02) 0.83 (0.57–1.19)
DH Stage II–III 0.94 (0.49–1.79) 0.72 (0.34–1.54) 0.89 (0.58–1.38)
PP 5 pulse pressure; MAP 5 mean arterial pressure; SBP 5 systolic blood pressure; DBP 5 diastolic blood pressure; ISH 5 isolated systolic hypertension; DH 5 diastolic
hypertension.
*No hypertension: SBP , 140 and DBP , 90 mm Hg; ISH Stage I: SBP 140–159 and DBP , 90 mm Hg; DH Stage I: DBP 90–99 mm Hg; ISH Stage II–III: SBP $
160 and DBP , 90 mm Hg; DH Stage II–III: DBP $ 100 mm Hg; †Reference.
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medication use to the models did not affect the PP effect.
Consistent with previous reports (14), the PP effect actually
tended to be stronger among individuals not taking antihy-
pertensive medications.
Mechanisms underlying the PP effect. The reasons for
the cardiovascular risk associated with a wide PP stand in
the hemodynamic changes that determine or accompany it.
A large PP is considered an indicator (or a consequence) of
aortic stiffening. Such stiffening, through a variety of mech-
anisms (8) tends to raise the SBP and lower the DBP. The
former, by increasing left ventricular pulsatile work, in-
creases end-systolic stress and myocardial oxygen demands
and promotes left ventricular hypertrophy, which in turn
can compromise diastolic relaxation and reduce left ventric-
ular ejection fraction. The latter reduces the pressure on
which coronary flow is dependent. Together, they increase
the vulnerability of the heart to ischemia and congestive
CHF. It should be noted, however, that while PP is a
correlate of arterial stiffness, it is not a direct measure of it,
because arterial stiffness can be assessed more directly by
means of pulse-wave velocity or other indicators of arterial
distensibility (36,37). These more direct assessments of
arterial stiffness have also been found to predict cardiovas-
cular risk (36,38).
In this study PP was a significant predictor of cardiovas-
cular events only when DBP was ,90 mm Hg, irrespective
of the level of SBP. Although this finding needs confirma-
tion, it may reflect the vulnerability of the elderly coronary
circulation to diastolic flow, especially in the presence of
increased pulsatile load (10). The coronary circulation is the
only circulation in which volume flow is governed by DBP
rather than SBP (39). Thus, any decrease in DBP, as a
consequence of increased arterial stiffness, may decrease
coronary blood flow, particularly in patients with coronary
stenosis, as is the case with many older adults. This finding
is consistent with previous studies showing that the effect of
PP is more marked among normotensive than hypertensive
individuals (13). Similarly, in older individuals the effect of
PP was found to be greater when MAP was normal rather
than high (10).
Because conduit vessel stiffness correlates with the pres-
ence and severity of atherosclerosis (36,38), increased PP
could be simply a marker for advanced atherosclerotic
disease. However, age-related increases in PP occur also in
populations in which the prevalence of atherosclerosis is low
(40), indicating that atherosclerosis is not a necessary
precursor of arterial stiffening. In our study, we eliminated
persons with previous history of MI or CHF, and we
adjusted for a number of other coronary risk factors and
comorbidities. Therefore, our results do not suggest that PP
is merely an indicator of advanced atherosclerosis.
Conclusions. Our study shows that PP, an easily obtain-
able correlate of arterial stiffness and pulsatile load, is an
independent predictor of incident CHD and CHF among
community elderly. Pulse pressure may complement the risk
stratification provided by current hypertension guidelines.
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Figure 3. Age- and sex-adjusted relative risks (RR) and 95% confidence intervals for the association between pulse pressure (PP) and incidence of coronary
heart disease (CHD), after stratification according to presence of hypertension (systolic blood pressure $ 140 or diastolic blood pressure $ 90 mm Hg)
and current use of antihypertensive medications (self-report use or current use of diuretics, beta-blockers, nitrates or nifedipine by direct inspection of
medications).
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